Correlation of amyloid beta and alpha-synuclein levels in human samples
December 2014
University of Bristol, Bristol, United Kingdom
Lewy bodies, widely present in Parkinson's disease, are often seen in Alzheimer-type pathologies. While Alzheimer's disease is characterized by an accumulation of amyloid-beta, Parkinson's is by an accumulation of alpha-synuclein. Some studies have also shown that the accumulation of these two aggregates can be correlated. Here, the correlation between amyloid-beta peptides and phosphorylation of alpha-synuclein is studied in postmortem human brain samples, from different cases of Parkinson's disease and dementia with Lewy bodies, and in a human neuroblastoma cell line overexpressing human alpha-synuclein. The results showed that insoluble and soluble phosphorylated alpha-synuclein correlated positively and negatively, respectively, with insoluble amyloid-beta. Moreover, amyloid-beta and insoluble phosphorylated alpha-synuclein levels were higher in demented than in non-demented patients. Insoluble alpha-synuclein also correlated positively with the Braak stage but negatively with the mini-mental state examination. Furthermore, neuroblastoma cells exposed to aggregated amyloid-beta 42 had increased levels of phosphorylated alpha-synuclein. In summary, this study shows that phosphorylated alpha-synuclein concentration in brain tissue correlates with amyloid-beta levels and with the dementia state, which could be potentially used to monitor the Lewy body disease-induced dementia.
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease
Seth Love
Added on: 09-10-2021
[1] https://alzres.biomedcentral.com/articles/10.1186/s13195-014-0077-y[2] https://data.jrc.ec.europa.eu/dataset/a8fd26ef-b113-47ab-92ba-fd2be449c7eb
